Warner-Lambert Company

Merck Sharp + Dohme Corp.

Godecke Akt.

Pfizer Products Inc.

Merck Sharp & Dohme LLC

Majid Mahjour

Mahdi B Fawzi

Zezhi Jesse Shao

Thomas Daniel Reynolds

Steven Diaz Santiago

Pushpa Ganapathi Shao

Howard N Bockbrader

Jiansheng Wan

Yun Hyung Cho

Feng Li

Uma R Iyer

Sutthilug Sotthivirat

Decheng Ma

Bernadette E Mauser

Kurt H Bauer

Russell U Nesbitt

David Hamilton Harris

David C Dubost

Justin Moser

Zahra A Rashidbaigi

Bhagwant Rege

Dan Zhang

Edwards E Linn

Lixia Cai

Yongjun Li

Bernadette Tedeschi

Haihong Fan

Dittmar Quade

Howard Norman Bockbrader

Ronald L Smith

Disclosed are pharmaceutical compositions comprising tedizolid phosphate, methods of preparing such pharmaceutical compositions, and methods of treating bacterial infections with such pharmaceutical compositions. Specifically, a pharmaceutical composition comprising tedizolid phosphate, an acid; and a suspending agent; and wherein the pH of the composition upon constitution with water is between about pH 2-4.5, is provided, wherein the acid is not citric acid or malic acid.

Pharmaceutical compositions of tedizolid phosphate

Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise:

Solid pharmaceutical compositions containing an integrase inhibitor

A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

Solid pharmaceutical compositions containing pregabalin

Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.

The instant invention relates to pharmaceutical compositions containing cathespin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.

Formulations for cathepsin K inhibitors

Novel pharmaceutical compositions are comprised of the salt or ion pair formation of a non-steroidal anti-inflammatory drug and an antihistamine or other decongestant. The physico-chemical characteristics of these compositions show them to be substantially different from their parent acid or base and will enable the preparation of dual action sustained or enhanced relief therapy regimens. The compositions also possessed enhanced stability and therefore the multi-symptom relief can be incorporated into a number of dosage forms such as capsules, tablets, elixirs, ointments and the like.

Salts/ion pairs of non-steroidal anti-inflammatory drugs in various

Penetration of various drugs through living membranes is improved by their use in transdermal compositions containing certain penetration-enhancing systems. A new delivery device is also described.

Compositions with enhanced penetration

The penetration of various drugs through living membranes, eg., skin, is improved by their use in topical compositions containing certain penetration-enhancer systems.

Penetration enhancement system

Saturated or unsaturated fatty acids of 8-18 carbon atoms or a C.sub.1 -C.sub.4 alkyl ester thereof in an aqueous system are described as skin absorption enhancers resulting in effective and non-irritating transdermal compositions comprising the above in combination with a therapeutically active ingredient.

Fatty acids and their small chain esters as penetration enhancers in

A method of enhancing penetration of a drug through the skin or other biological membranes using lecithin is herein described along with pharmaceutical compositions containing effective amounts of lecithin as a penetration enhancer.

Use of commercial lecithin as skin penetration enhancer

The use of permeation enhancers permits the formulation of transdermal dosage forms for calcium antagonists. These dosage forms are administrable to humans and other mammals, e.g., bovines.

Transdermal application form of calcium antagonists

3-phenoxypyridine and its salts are useful in transdermal formulations as cognition activators.

Growing community of inventors

Schwenksville, PA, United States of America

Majid Mahjour